WO2015069110A1 - Multiples a(nta)gonistes de d2/antagonistes de h3 pour le traitement de troubles associés au snc - Google Patents

Multiples a(nta)gonistes de d2/antagonistes de h3 pour le traitement de troubles associés au snc Download PDF

Info

Publication number
WO2015069110A1
WO2015069110A1 PCT/NL2014/050772 NL2014050772W WO2015069110A1 WO 2015069110 A1 WO2015069110 A1 WO 2015069110A1 NL 2014050772 W NL2014050772 W NL 2014050772W WO 2015069110 A1 WO2015069110 A1 WO 2015069110A1
Authority
WO
WIPO (PCT)
Prior art keywords
mmol
mixture
added
dihydrobenzo
concentrated
Prior art date
Application number
PCT/NL2014/050772
Other languages
English (en)
Inventor
André Heeres
Sandra WILLIGERS - Hogg
Marcus Leonardus Gerardus BORST
Melloney Joyce DRÖGE
Original Assignee
Aapa B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aapa B.V. filed Critical Aapa B.V.
Publication of WO2015069110A1 publication Critical patent/WO2015069110A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des composés répondant à la formule (III), et leurs sels, hydrates et solvats pharmaceutiquement acceptables. Les composés ont des effets antagonistes/agonistes (partiels) du récepteur D2 et des effets antagonistes de H3. L'invention concerne des compositions pharmaceutiques de ces composés et des procédés pour les utiliser pour une application dans la prophylaxie ou le traitement de troubles du SNC.
PCT/NL2014/050772 2013-11-07 2014-11-07 Multiples a(nta)gonistes de d2/antagonistes de h3 pour le traitement de troubles associés au snc WO2015069110A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13191917 2013-11-07
EP13191917.7 2013-11-07

Publications (1)

Publication Number Publication Date
WO2015069110A1 true WO2015069110A1 (fr) 2015-05-14

Family

ID=49518865

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2014/050772 WO2015069110A1 (fr) 2013-11-07 2014-11-07 Multiples a(nta)gonistes de d2/antagonistes de h3 pour le traitement de troubles associés au snc

Country Status (1)

Country Link
WO (1) WO2015069110A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10689371B2 (en) 2018-04-18 2020-06-23 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US11919912B2 (en) 2018-05-21 2024-03-05 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004035556A1 (fr) * 2002-10-16 2004-04-29 Glaxo Group Limited Piperazines, (1,4) diazepines, et 2,5-diazabicyclo (2.2.1) heptanes substitues en tant qu'antagonistes de l'histamine h1 et/ou h3 ou antagonistes inverses de l'histamine h3
WO2012003418A2 (fr) * 2010-07-02 2012-01-05 The University Of North Carolina At Chapel Hill Ligands fonctionnellement sélectifs des récepteurs d2 de dopamine

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004035556A1 (fr) * 2002-10-16 2004-04-29 Glaxo Group Limited Piperazines, (1,4) diazepines, et 2,5-diazabicyclo (2.2.1) heptanes substitues en tant qu'antagonistes de l'histamine h1 et/ou h3 ou antagonistes inverses de l'histamine h3
WO2012003418A2 (fr) * 2010-07-02 2012-01-05 The University Of North Carolina At Chapel Hill Ligands fonctionnellement sélectifs des récepteurs d2 de dopamine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YAN Y ET AL: "Potent dihydroquinolinone dopamine D2 partial agonist/serotonin reuptake inhibitors for the treatment of schizophrenia", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 20, no. 9, 1 May 2010 (2010-05-01), pages 2983 - 2986, XP027012878, ISSN: 0960-894X, [retrieved on 20100303] *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10689371B2 (en) 2018-04-18 2020-06-23 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US11274095B2 (en) 2018-04-18 2022-03-15 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US11919912B2 (en) 2018-05-21 2024-03-05 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof

Similar Documents

Publication Publication Date Title
US9776974B2 (en) Inhibitors of lysine specific demethylase-1
KR102438302B1 (ko) 리신 특이적 데메틸라제-1의 억제제
KR102012057B1 (ko) Lrrk2 조절제로서 아미노피리미딘 유도체
CA2710234C (fr) Triazoles substitues par heteroaryle polycyclique utiles comme inhibiteurs de axl
EP1928236B1 (fr) Composes et compositions contenant de la diarylamine, et utilisation en tant que modulateurs de recepteurs de c-kit
AU2009287621B2 (en) Tri-substituted pyrimidine compounds and their use as PDE10 inhibitors
EP3813819A1 (fr) Inhibiteurs de kinases dépendantes des cyclines
CA2935071A1 (fr) Derives de piperidine-dione
AU2013363957A1 (en) Histone demethylase inhibitors
KR101663635B1 (ko) 크로몬 유도체, 그 제조방법 및 그들의 치료 분야
AU2011260323A1 (en) Aminopyrimidine derivatives as LRRK2 modulators
US20150166523A1 (en) Branched chain alkyl heteroaromatic ring derivative
US8835436B2 (en) Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same
JPWO2004110986A1 (ja) ベンズアミド誘導体又はその塩
KR20120112618A (ko) 치환된 이소퀴놀리논 및 퀴나졸리논
AU2006275568A1 (en) Dipiperazinyl ketones and related analogues
CA2785284A1 (fr) Nouveau derive aryl-uree
WO2015152367A1 (fr) Dérivé cyclique oxo-hétérocyclique
CA3158079A1 (fr) Agonistes de trpml1 heterocycliques
JP2017100951A (ja) オキサゾリジノン及びオキサジナノン誘導体
WO2015069110A1 (fr) Multiples a(nta)gonistes de d2/antagonistes de h3 pour le traitement de troubles associés au snc
JP2014141480A (ja) メチルピペリジン誘導体を含有する医薬
JP2015131802A (ja) 分岐鎖アルキルヘテロ芳香環誘導体を含有する医薬
CA2929742C (fr) Quinazolines substituees par une sulfoximine destinees a des compositions pharmaceutiques
EP3619200A1 (fr) Antagonistes hétérocycliques de p2x7

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14800166

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14800166

Country of ref document: EP

Kind code of ref document: A1